文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期，新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

靶向肿瘤细胞内在的CTRP6仿生共递送协同增强铁死亡和免疫激活，以提高肺癌中抗PD-L1免疫治疗的疗效。

Targeted tumor cell-intrinsic CTRP6 biomimetic codelivery synergistically amplifies ferroptosis and immune activation to boost anti-PD-L1 immunotherapy efficacy in lung cancer.

作者信息

Cai Songhua, Huang Jing, Fan Hongjie, Sui Zhilin, Huang Chujian, Deng Youjun, Jia Ran, Wang Lixu, Ma Kai, Guo Xiaotong, He Jie, Zhang Baihua, Yu Zhentao

机构信息

Department of Thoracic Surgery, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital & Shenzhen Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Shenzhen, 518116, China.

Department of Radiology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.

出版信息

J Nanobiotechnology. 2025 Jun 2;23(1):409. doi: 10.1186/s12951-025-03428-5.

DOI:10.1186/s12951-025-03428-5
PMID:40457410
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC12131836/
Abstract

BACKGROUND: Lung adenocarcinoma (LUAD) is a refractory tumor with high incidence, high mortality, and easy development of drug resistance. Represented by PD-L1, the rise of immunotherapy and multidrug combinations offers a reliable approach to treating LUAD. However, there are still some patients with immunoresistance or insensitivity, and new combination therapies are still needed. METHODS: In this study, cyclic arginine-glycine-aspartate (cRGD)/erythrocyte membrane (RBCM) double-head nanocarriers were designed. This nanocarrier platform targets CTRP6 in tumors and delivers gemcitabine to block the progression of lung cancer. PD-L1 monoclonal antibodies were used as a codelivery platform to explore the effect of the codelivery platform on immunotherapy. RESULTS: CTRP6 expression was negatively correlated with the prognosis of patients with lung adenocarcinoma. The codelivery platform @RBCM/cRGD-PhLips effectively targeted tumor cells. Co-carrying gemcitabine and targeting CTRP6 expression, it amplified ferroptosis of tumor cells through the NRF2/STAT3 signaling pathway, activated intratumoral immunity, and promoted M1-like macrophage transformation and CD8 T-cell recruitment. This platform amplified the immune effect of PD-L1 monoclonal antibodies to play an anti-lung cancer role. CONCLUSIONS: The synergistic delivery of the targeted tumor cell-intrinsic CTRP6 biomimetic nanocarrier provides a new approach to the combined immunotherapy of lung cancer.

摘要

背景：肺腺癌（LUAD）是一种难治性肿瘤，具有高发病率、高死亡率且易产生耐药性。以程序性死亡受体配体1（PD-L1）为代表，免疫疗法和多药联合的兴起为治疗肺腺癌提供了一种可靠的方法。然而，仍有一些患者存在免疫抵抗或不敏感情况，仍需要新的联合治疗方法。 方法：在本研究中，设计了环状精氨酸-甘氨酸-天冬氨酸（cRGD）/红细胞膜（RBCM）双头纳米载体。该纳米载体平台靶向肿瘤中的卷曲霉素相关蛋白6（CTRP6），并递送吉西他滨以阻断肺癌进展。使用PD-L1单克隆抗体作为共递送平台，以探究该共递送平台对免疫治疗的效果。 结果：CTRP6表达与肺腺癌患者的预后呈负相关。共递送平台@RBCM/cRGD-PhLips有效靶向肿瘤细胞。共携带吉西他滨并靶向CTRP6表达，它通过核因子E2相关因子2（NRF2）/信号转导和转录激活因子3（STAT3）信号通路放大肿瘤细胞的铁死亡，激活肿瘤内免疫，并促进M1型巨噬细胞转化和CD8 T细胞募集。该平台放大了PD-L1单克隆抗体的免疫效果，发挥抗肺癌作用。 结论：靶向肿瘤细胞内源性CTRP6的仿生纳米载体的协同递送为肺癌联合免疫治疗提供了一种新方法。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/37e7/12131836/136ede76683b/12951_2025_3428_Fig9_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/37e7/12131836/37b643f2f013/12951_2025_3428_Sch1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/37e7/12131836/c6cf8a44ad18/12951_2025_3428_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/37e7/12131836/4bdf23254835/12951_2025_3428_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/37e7/12131836/0adf5a6f4d2e/12951_2025_3428_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/37e7/12131836/d665127fe836/12951_2025_3428_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/37e7/12131836/8ba0aec72bd0/12951_2025_3428_Fig5_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/37e7/12131836/c050ac422662/12951_2025_3428_Fig6_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/37e7/12131836/bc507c68c466/12951_2025_3428_Fig7_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/37e7/12131836/61de14e1b840/12951_2025_3428_Fig8_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/37e7/12131836/136ede76683b/12951_2025_3428_Fig9_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/37e7/12131836/37b643f2f013/12951_2025_3428_Sch1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/37e7/12131836/c6cf8a44ad18/12951_2025_3428_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/37e7/12131836/4bdf23254835/12951_2025_3428_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/37e7/12131836/0adf5a6f4d2e/12951_2025_3428_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/37e7/12131836/d665127fe836/12951_2025_3428_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/37e7/12131836/8ba0aec72bd0/12951_2025_3428_Fig5_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/37e7/12131836/c050ac422662/12951_2025_3428_Fig6_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/37e7/12131836/bc507c68c466/12951_2025_3428_Fig7_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/37e7/12131836/61de14e1b840/12951_2025_3428_Fig8_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/37e7/12131836/136ede76683b/12951_2025_3428_Fig9_HTML.jpg

相似文献

[1]
Targeted tumor cell-intrinsic CTRP6 biomimetic codelivery synergistically amplifies ferroptosis and immune activation to boost anti-PD-L1 immunotherapy efficacy in lung cancer.

J Nanobiotechnology. 2025-6-2

[2]
Targeted Positron Emission Tomography-Tracked Biomimetic Codelivery Synergistically Amplifies Ferroptosis and Pyroptosis for Inducing Lung Cancer Regression and Anti-PD-L1 Immunotherapy Efficacy.

ACS Nano. 2024-11-12

[3]
Dysregulated ferroptosis-related genes indicate potential clinical benefits for anti-PD-1/PD-L1 immunotherapy in lung adenocarcinoma.

J Clin Lab Anal. 2021-12

[4]
LRP1B Suppresses Immunotherapy Efficacy in Lung Adenocarcinoma by Preventing Ferroptosis.

Cancer Med. 2024-12

[5]
Targeting PFKFB4 Biomimetic Codelivery System Synergistically Enhances Ferroptosis to Suppress Small Cell Lung Cancer and Augments the Efficacy of Anti-PD-L1 Immunotherapy.

Adv Sci (Weinh). 2025-6

[6]
The impact of POSTN on tumor cell behavior and the tumor microenvironment in lung adenocarcinoma.

Int Immunopharmacol. 2025-1-3

[7]
ILT4 inhibition prevents TAM- and dysfunctional T cell-mediated immunosuppression and enhances the efficacy of anti-PD-L1 therapy in NSCLC with EGFR activation.

Theranostics. 2021

[8]
PD-L1 and CD47 co-expression predicts survival and enlightens future dual-targeting immunotherapy in non-small cell lung cancer.

Thorac Cancer. 2021-6

[9]
SLC7A11 inhibits ferroptosis and downregulates PD-L1 levels in lung adenocarcinoma.

Front Immunol. 2024-4-9

[10]
BATF-Activated AIM2 Mediates Immune Escape in Lung Adenocarcinoma by Regulating PD-L1.

Int Arch Allergy Immunol. 2025

本文引用的文献

[1]
MELK prevents radiofrequency ablation-induced immunogenic cell death and antitumor immune response by stabilizing FABP5 in hepatocellular malignancies.

Mil Med Res. 2025-1-27

[2]
Tumor-related factor complement Clq/TNF-related protein 6 affects the development of digestive system tumors through the phosphatidylinositol 3-kinase pathway.

World J Gastroenterol. 2024-7-14

[3]
Targeting KRASG12D mutation in non-small cell lung cancer: molecular mechanisms and therapeutic potential.

Cancer Gene Ther. 2024-7

[4]
TMEM9 promotes lung adenocarcinoma progression via activating the MEK/ERK/STAT3 pathway to induce VEGF expression.

Cell Death Dis. 2024-4-25

[5]
CTRP6 promotes the macrophage inflammatory response, and its deficiency attenuates LPS-induced inflammation.

J Biol Chem. 2024-1

[6]
CTRP6 protects against ferroptosis to drive lung cancer progression and metastasis by destabilizing SOCS2 and augmenting the xCT/GPX4 pathway.

Cancer Lett. 2023-11-28

[7]
KEAP1 mutation in lung adenocarcinoma promotes immune evasion and immunotherapy resistance.

Cell Rep. 2023-11-28

[8]
Regulation of Ferroptosis in Lung Adenocarcinoma.

Int J Mol Sci. 2023-9-27

[9]
CTRP6 regulates M1 macrophage polarization via the PPAR-γ/NF-κB pathway and reprogramming glycolysis in recurrent spontaneous abortion.

Int Immunopharmacol. 2023-11

[10]
Macrophage-organoid co-culture model for identifying treatment strategies against macrophage-related gemcitabine resistance.

J Exp Clin Cancer Res. 2023-8-9

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索